Metastatic thoracic lymph node carcinoma of unknown origin

Kentaroh Miyoshi, Norihito Okumura, Yujiro Kokado, Tomoaki Matsuoka, Kotaro Kameyama, Tatsuo Nakagawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. Metastatic thoracic lymph node carcinoma of unknown origin is rare. Some surgical cases which had better outcome than expected were reported in the literature. However, the reason for this unexpected outcome, the etiology, and preferable treatment are unclear. We present a review of our cases. Methods. In the past 20 years, we encountered 8 cases of thoracic lymph node carcinoma of unknown origin. Here we review the clinical course, treatment, and outcome. Results. Four out of 8 patients had single station lymph node carcinoma (SS). Three patients had multistation lesions (MS). One patient had single station lesion with malignant pleural effusion (SS + MPE). SS cases underwent complete excision of the focal lymph node without additional therapy. MS cases underwent chemotherapy or radiation therapy after biopsy. The SS + MPE case received excision of the focal lymph node with additional chemotherapy. All patients in the SS group had long day survival without carcinoma bearing (21-108 months). All patients in the MS group died due to cancer within 1 year (mean survival time: 9.3 months). The SS + MPE patient survived 17 months with carcinoma. Conclusion. A single hilar lesion and complete excision may lead to a good outcome. Thoracic lymph node lesions should be surgically excised if complete excision is possible.

Original languageEnglish
Pages (from-to)245-250
Number of pages6
JournalJapanese Journal of Lung Cancer
Volume47
Issue number3
DOIs
Publication statusPublished - Jun 2007
Externally publishedYes

Fingerprint

Thorax
Lymph Nodes
Carcinoma
Lymph Node Excision
Malignant Pleural Effusion
Drug Therapy
Radiotherapy
Survival Rate
Biopsy
Survival
Therapeutics
Neoplasms

Keywords

  • Complete excision
  • Metastatic carcinoma of unknown origin
  • Thoracic lymph node

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Miyoshi, K., Okumura, N., Kokado, Y., Matsuoka, T., Kameyama, K., & Nakagawa, T. (2007). Metastatic thoracic lymph node carcinoma of unknown origin. Japanese Journal of Lung Cancer, 47(3), 245-250. https://doi.org/10.2482/haigan.47.245

Metastatic thoracic lymph node carcinoma of unknown origin. / Miyoshi, Kentaroh; Okumura, Norihito; Kokado, Yujiro; Matsuoka, Tomoaki; Kameyama, Kotaro; Nakagawa, Tatsuo.

In: Japanese Journal of Lung Cancer, Vol. 47, No. 3, 06.2007, p. 245-250.

Research output: Contribution to journalArticle

Miyoshi, K, Okumura, N, Kokado, Y, Matsuoka, T, Kameyama, K & Nakagawa, T 2007, 'Metastatic thoracic lymph node carcinoma of unknown origin', Japanese Journal of Lung Cancer, vol. 47, no. 3, pp. 245-250. https://doi.org/10.2482/haigan.47.245
Miyoshi, Kentaroh ; Okumura, Norihito ; Kokado, Yujiro ; Matsuoka, Tomoaki ; Kameyama, Kotaro ; Nakagawa, Tatsuo. / Metastatic thoracic lymph node carcinoma of unknown origin. In: Japanese Journal of Lung Cancer. 2007 ; Vol. 47, No. 3. pp. 245-250.
@article{4b311fe399954e10b970e89fb42e6a13,
title = "Metastatic thoracic lymph node carcinoma of unknown origin",
abstract = "Objective. Metastatic thoracic lymph node carcinoma of unknown origin is rare. Some surgical cases which had better outcome than expected were reported in the literature. However, the reason for this unexpected outcome, the etiology, and preferable treatment are unclear. We present a review of our cases. Methods. In the past 20 years, we encountered 8 cases of thoracic lymph node carcinoma of unknown origin. Here we review the clinical course, treatment, and outcome. Results. Four out of 8 patients had single station lymph node carcinoma (SS). Three patients had multistation lesions (MS). One patient had single station lesion with malignant pleural effusion (SS + MPE). SS cases underwent complete excision of the focal lymph node without additional therapy. MS cases underwent chemotherapy or radiation therapy after biopsy. The SS + MPE case received excision of the focal lymph node with additional chemotherapy. All patients in the SS group had long day survival without carcinoma bearing (21-108 months). All patients in the MS group died due to cancer within 1 year (mean survival time: 9.3 months). The SS + MPE patient survived 17 months with carcinoma. Conclusion. A single hilar lesion and complete excision may lead to a good outcome. Thoracic lymph node lesions should be surgically excised if complete excision is possible.",
keywords = "Complete excision, Metastatic carcinoma of unknown origin, Thoracic lymph node",
author = "Kentaroh Miyoshi and Norihito Okumura and Yujiro Kokado and Tomoaki Matsuoka and Kotaro Kameyama and Tatsuo Nakagawa",
year = "2007",
month = "6",
doi = "10.2482/haigan.47.245",
language = "English",
volume = "47",
pages = "245--250",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "3",

}

TY - JOUR

T1 - Metastatic thoracic lymph node carcinoma of unknown origin

AU - Miyoshi, Kentaroh

AU - Okumura, Norihito

AU - Kokado, Yujiro

AU - Matsuoka, Tomoaki

AU - Kameyama, Kotaro

AU - Nakagawa, Tatsuo

PY - 2007/6

Y1 - 2007/6

N2 - Objective. Metastatic thoracic lymph node carcinoma of unknown origin is rare. Some surgical cases which had better outcome than expected were reported in the literature. However, the reason for this unexpected outcome, the etiology, and preferable treatment are unclear. We present a review of our cases. Methods. In the past 20 years, we encountered 8 cases of thoracic lymph node carcinoma of unknown origin. Here we review the clinical course, treatment, and outcome. Results. Four out of 8 patients had single station lymph node carcinoma (SS). Three patients had multistation lesions (MS). One patient had single station lesion with malignant pleural effusion (SS + MPE). SS cases underwent complete excision of the focal lymph node without additional therapy. MS cases underwent chemotherapy or radiation therapy after biopsy. The SS + MPE case received excision of the focal lymph node with additional chemotherapy. All patients in the SS group had long day survival without carcinoma bearing (21-108 months). All patients in the MS group died due to cancer within 1 year (mean survival time: 9.3 months). The SS + MPE patient survived 17 months with carcinoma. Conclusion. A single hilar lesion and complete excision may lead to a good outcome. Thoracic lymph node lesions should be surgically excised if complete excision is possible.

AB - Objective. Metastatic thoracic lymph node carcinoma of unknown origin is rare. Some surgical cases which had better outcome than expected were reported in the literature. However, the reason for this unexpected outcome, the etiology, and preferable treatment are unclear. We present a review of our cases. Methods. In the past 20 years, we encountered 8 cases of thoracic lymph node carcinoma of unknown origin. Here we review the clinical course, treatment, and outcome. Results. Four out of 8 patients had single station lymph node carcinoma (SS). Three patients had multistation lesions (MS). One patient had single station lesion with malignant pleural effusion (SS + MPE). SS cases underwent complete excision of the focal lymph node without additional therapy. MS cases underwent chemotherapy or radiation therapy after biopsy. The SS + MPE case received excision of the focal lymph node with additional chemotherapy. All patients in the SS group had long day survival without carcinoma bearing (21-108 months). All patients in the MS group died due to cancer within 1 year (mean survival time: 9.3 months). The SS + MPE patient survived 17 months with carcinoma. Conclusion. A single hilar lesion and complete excision may lead to a good outcome. Thoracic lymph node lesions should be surgically excised if complete excision is possible.

KW - Complete excision

KW - Metastatic carcinoma of unknown origin

KW - Thoracic lymph node

UR - http://www.scopus.com/inward/record.url?scp=34547632117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547632117&partnerID=8YFLogxK

U2 - 10.2482/haigan.47.245

DO - 10.2482/haigan.47.245

M3 - Article

AN - SCOPUS:34547632117

VL - 47

SP - 245

EP - 250

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 3

ER -